HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Hua, S.-C. Articles by Chang, T.-C. Search for Related Content PubMed PubMed Citation Articles by Hua, S.-C. Articles by Chang, T.-C.

Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly

Division of Endocrinology and Metabolism, Department of Internal Medicine, Chia-Yi Christian Hospital, No. 539, Jhongsiao Road, Chiayi City 60002, Taiwan and ¹ Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, No. 7, Chung-Shan South Road, Taipei 10002, Taiwan

(Correspondence should be addressed to T-C Chang; Email: tcchang{at}ha.mc.ntu.edu.tw)

Objective: Acromegaly has an important impact on quality of life (QOL). The aim of this study was to evaluate the associations of remission status and lanreotide treatment with QOL in patients with treated acromegaly, by the newly developed disease-generated acromegaly QOL questionnaire (ACROQOL).

Design: Cross-sectional study.

Methods: Fifty-two patients with treated acromegaly were recruited to complete the Chinese version of the ACROQOL translated and validated from the English version. These patients were divided into controlled and uncontrolled groups based on the latest remission criteria and further subdivided into four groups according to the present treatment with lanreotide or not. Comparisons between groups were analyzed.

Results: There was no difference between controlled and uncontrolled groups in the ACROQOL scores of total score, both scales and psychological subscales. However, in the controlled group, present treatment with lanreotide, in comparison with no treatment, showed worse ACROQOL scores in total score (P = 0.021), psychological scale (P = 0.011), psychological subscale ‘appearance’ (P = 0.032) and ‘personal relations’ (P = 0.010).

Conclusions: The lanreotide treatment was negatively associated with QOL in biochemically controlled acromegalic patients, especially in the psychological aspect.

This article has been cited by other articles:

				S. J. C. M. M. Neggers, M. O. van Aken, W. W. de Herder, R. A. Feelders, J. A. M. J. L. Janssen, X. Badia, S. M. Webb, and A. J. van der Lely Quality of Life in Acromegalic Patients during Long-Term Somatostatin Analog Treatment with and without Pegvisomant J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3853 - 3859. [Abstract] [Full Text] [PDF]

				M. P Matta, E. Couture, L. Cazals, D. Vezzosi, A. Bennet, and P. Caron Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance Eur. J. Endocrinol., March 1, 2008; 158(3): 305 - 310. [Abstract] [Full Text] [PDF]

				G. T'Sjoen, M. Bex, D. Maiter, B. Velkeniers, and R. Abs Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian Registry on acromegaly Eur. J. Endocrinol., October 1, 2007; 157(4): 411 - 417. [Abstract] [Full Text] [PDF]